# ATHEM (NCT05165355)

> Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma

No report yet. It can be ordered.

- Drugs tested: furmonertinib
- Indication: resected EGFR-mutant stage IB-IIA non-small cell lung carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05165355
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Tongji University
- Conditions: NSCLC; EGF-R Positive Non-Small Cell Lung Cancer
- Interventions: Furmonertinib
- Enrollment: 90
- Primary outcome: Disease Free Survival (DFS) rate at 2 years

## Indexed commentary on ATHEM so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=athem-nct05165355
